General
Preferred name
ALOGLIPTIN
Synonyms
CHEMBL376359 ()
SYR 322 ()
Alogliptin(SYR-322)benzoate ()
SYR-322 ()
Alogliptin（SYR-322） ()
Alogliptin£¨SYR-322£©benzoate ()
Alogliptin??SYR-322?? ()
ALOGLIPTIN BENZOATE ()
Alogliptin (Benzoate) ()
SYR-322 (free base) ()
Alogliptin (SYR-322) benzoate ()
Alogliptin (benzoate salt) ()
Alogliptin (as benzoate) ()
Alogliptin benzoate component of kazano ()
Vipidia ()
Nesina ()
Alogliptin benzoate component of oseni ()
Alogliptina ()
Alogliptine ()
ALOGLIPTINA ()
ALOGLIPTINE ()
VIPIDIA ()
P&D ID
PD009323
CAS
850649-61-5
1246610-75-2
850649-62-6
Tags
available
probe
drug
Approved by
FDA
First approval
2013
Drug indication
Type-2 diabetes
type 2 diabetes mellitus
diabetes mellitus
Drug Status
approved
Max Phase
4.0
Probe info
Probe type
P&D approved
calculated probe
Probe selectivity
protein-selective
Probe sources
High-quality chemical probes
Tool Compound Set
Probe targets
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Alogliptin Benzoate (SYR-322) is a potent, selective and orally active inhibitor of DPP-4 with an IC50 of <10 nM, and exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9. Alogliptin Benzoate can be used for the research of type 2 diabetes[1][2][3].
PRICE 53
ABSORPTION The pharmacokinetics of NESINA was also shown to be similar in healthy subjects and in patients with type 2 diabetes. When single, oral doses up to 800 mg in healthy subjects and type 2 diabetes patients are given, the peak plasma alogliptin concentration (median Tmax) occurred 1 to 2 hours after dosing. Accumulation of aloglipin is minimal. The absolute bioavailability of NESINA is approximately 100%. Food does not affect the absorption of alogliptin. ;
DESCRIPTION Alogliptin is a once-daily, oral dipeptidyl peptidase-4 (DPP-4) inhibitor class anti-diabetic drug. (GtoPdb)
DESCRIPTION Alogliptin (SYR-322 free base) is a potent, selective and orally active inhibitor of DPP-4 with an IC50 of <10 nM, and exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9. Alogliptin can be used for the research of type 2 diabetes[1][2][3].
PRICE 51
DESCRIPTION Alogliptin Benzoate (SYR 322)(SYR 322), an effective and specific DPP-4 inhibitor (IC50<10 nM), exhibits greater than 10, 000-fold selectivity over DPP-8/9. Alogliptin may inhibit inflammatory responses by preventing the toll-like receptor 4 (TLR-4)-mediated formation of proinflammatory cytokines. (TargetMol Bioactive Compound Library)
DESCRIPTION Alogliptin is a dipeptidyl peptidase-4 inhibitor used to treat hyperglycemia in patients with type 2 diabetes mellitus. (Enamine Bioactive Compounds)
DESCRIPTION Alogliptin (SYR-322)(SYR-322) is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10, 000-fold selectivity over DPP-8 and DPP-9. (TargetMol Bioactive Compound Library)
Compound Sets
26
AdooQ Bioactive Compound Library
A13311
A13571
Axon Medchem Screening Library
3310
Cayman Chemical Bioactives
23768
ChEMBL Approved Drugs
CHEMBL227529
CHEMBL376359
ChEMBL Drugs
CHEMBL227529
CHEMBL376359
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB06203
DrugBank Approved Drugs
DB06203
DrugCentral
4340
DrugCentral Approved Drugs
4340
DrugMAP
DM8WI3R
DrugMAP Approved Drugs
DM8WI3R
Enamine Bioactive Compounds
EBC-26650
EU-OPENSCREEN Bioactive Compound Library
EOS101628
EUbOPEN Chemogenomics Library
EUB0002492
Guide to Pharmacology
6319
High-quality chemical probes
PD009323
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL376359
MedChem Express Bioactive Compound Library
HY-A0023
HY-A0023A
NCATS Inxight Approved Drugs
JHC049LO86
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
Selleckchem Bioactive Compound Library
alogliptin
alogliptin-syr-322
TargetMol Bioactive Compound Library
T2401
T6192
Tool Compound Set
External IDs
57
Properties
(calculated by RDKit )
Molecular Weight
339.17
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
1
Rotatable Bonds
3
Ring Count
3
Aromatic Ring Count
2
cLogP
0.39
TPSA
97.05
Fraction CSP3
0.39
Chiral centers
1.0
Largest ring
6.0
QED
0.87
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Dipeptidyl peptidase IV
Dipeptidyl Peptidase
DPP-4
Ferroptosis
DPP4
DPP-4 inhibitor
DPP
Member status
member
MOA
Dipeptidyl Peptidase IV (CD26
DPP-IV
DP-IV) Inhibitors
dipeptidyl peptidase inhibitor
Indication
diabetes mellitus
Pathway
Apoptosis
Proteases/Proteasome
Ubiquitination
Metabolic Enzyme/Protease
Recommended Cell Concentration
None
Source data